Pd25-06 a Significant Proportion of Interstitial Cystitis/Bladder Pain Syndrome Patients Have Sustained Symptom Improvement Following Therapeutic Hydrodistension

You have accessJournal of UrologyInfections/Inflammation/Cystic Disease of the Genitourinary Tract: Interstitial Cystitis (PD25)1 May 2024PD25-06 A SIGNIFICANT PROPORTION OF INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME PATIENTS HAVE SUSTAINED SYMPTOM IMPROVEMENT FOLLOWING THERAPEUTIC HYDRODISTENSION Dylan T. Wolff, Robert J. Evans, Gopal Badlani, Carl Langefeld, Julie Ziegler, and Stephen J. Walker Dylan T. WolffDylan T. Wolff , Robert J. EvansRobert J. Evans , Gopal BadlaniGopal Badlani , Carl LangefeldCarl Langefeld , Julie ZieglerJulie Ziegler , and Stephen J. WalkerStephen J. Walker View All Author Informationhttps://doi.org/10.1097/01.JU.0001008584.88541.ff.06AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Cystoscopy under anesthesia with 5 minute hydrodistension (HOD) is a treatment option for interstitial cystitis/bladder pain syndrome (IC/BPS) patients. There is a paucity of high level evidence to support the efficacy of this treatment. The objective of this longitudinal study was to assess the level and duration of positive response to HOD in a large IC/BPS cohort. METHODS: 124 female patients with IC/BPS scheduled for HOD were enrolled in this prospective IRB-approved study. Participants answered a set of validated questionnaires (including global response assessment (GRA), O'Leary Sant Interstitial Cystitis Symptom and Problem Indices (ICSI/ICPI), and Female Genitourinary Pain Index (F-GUPI)), at intake and then again at 1, 2-, 3-, 6-, and 12-months post-treatment. The primary outcome measure was based on GRA, a patient reporting symptom improvement of "mild", "moderate", or "marked", compared to baseline, was considered a "responder". Secondary outcomes were assessed based on a significant change in scores on ICSI, ICPI, and F-GUPI. At each time point, the mean change in validated questionnaire symptom scores (compared to baseline) was compared between responders and non-responders using Wilcoxon Rank Sum tests, with a p-value <0.05 considered statistically significant. RESULTS: The number of patients that completed validated GRA assessment at 1-month post-HOD was 115, followed by 101 at 2 months, 91 at 3 months, 78 at 6 months, and 49 at 12 months. Overall demographic (e.g., age, race) and clinical characteristics (e.g., anesthetic bladder capacity, Hunner lesion status, frequency of non-urologic syndromes) were similar between responders and non-responders at any time point. At 1-month post-HOD, 62 patients (53.9%) reported persistent positive response to treatment (i.e., were responders), while 21/49 (42%) respondents continued to report a positive response at 12 months. Patients classified as responders, when compared to non-responders, continued to have significantly improved ICSI, ICPI, and F-GUPI scores through the 3 month follow up point (p<0.05). CONCLUSIONS: For a large subset of IC/BPS patients, therapeutic hydrodistension results in a clinically meaningful and sustained improvement in associated symptoms and pain. Source of Funding: Subcontract from 5U01DK082316-08; R01 DK124599 © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e538 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Dylan T. Wolff More articles by this author Robert J. Evans More articles by this author Gopal Badlani More articles by this author Carl Langefeld More articles by this author Julie Ziegler More articles by this author Stephen J. Walker More articles by this author Expand All Advertisement PDF downloadLoading ...